GlassScriptPhysician profile
Karin Lebess
NPI 1942633300
$1,178.07
in general payments reported to CMS, 2019-2025
13 companies · $473 in 2025
The $473 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.26 · 2022: $135 · 2023: $360 · 2024: $191 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $926 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $925.65 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $359.61 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $132.56 | 2021-2025 | |
| Pfizer INC. | $114.35 | 2022-2025 | |
| Astellas Pharma US INC | $99.00 | 2024 | |
| Millicent US INC | $94.93 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Hologic Sales and Service, LLC | $85.18 | 2022-2025 | Myosure Tissue Removal Device, Aptima, Thinprep 2000 Processor |
| Biogen, INC. | $78.65 | 2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $71.30 | 2023-2025 | Myfembree, Gemtesa |
| Myovant Sciences INC. | $52.59 | 2022 | |
| Organon LLC | $42.38 | 2023-2024 | Nexplanon |
| Abbvie INC. | $18.51 | 2022 | |
| Coopersurgical, INC. | $16.20 | 2025 | Paragard T 380a |
| Exeltis, USA INC. | $12.81 | 2023 | Nuvessa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karin Lebess listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.